share_log

Alliance Global Partners Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $4

Alliance Global Partners Initiates Coverage On Akari Therapeutics With Buy Rating, Announces Price Target of $4

联盟全球合作伙伴以买入评级启动对Akari Therapeutics的报道,宣布目标股价为4美元
Benzinga Real-time News ·  2022/11/01 08:58

Alliance Global Partners analyst James Molloy initiates coverage on Akari Therapeutics (NASDAQ:AKTX) with a Buy rating and announces Price Target of $4.

Alliance Global Partners分析师詹姆斯·莫洛伊以买入评级开始报道Akari Therapeutics(纳斯达克股票代码:AKTX),并宣布目标股价为4美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发